高级搜索

非手术治疗食管癌的临床分期研究

朱青山, 申静, 王能超, 何志杰, 张庆富, 冯连杰

朱青山, 申静, 王能超, 何志杰, 张庆富, 冯连杰. 非手术治疗食管癌的临床分期研究[J]. 肿瘤防治研究, 2013, 40(02): 168-171. DOI: 10.3971/j.issn.1000-8578.2013.02.011
引用本文: 朱青山, 申静, 王能超, 何志杰, 张庆富, 冯连杰. 非手术治疗食管癌的临床分期研究[J]. 肿瘤防治研究, 2013, 40(02): 168-171. DOI: 10.3971/j.issn.1000-8578.2013.02.011
Zhu Qingshan, Shen Jing, Wang Nengchao, He Zhijie, Zhang Qingfu, Feng Lianjie. Study of Clinical Staging of Esophageal Cancer Treated by Non-surgical Methods[J]. Cancer Research on Prevention and Treatment, 2013, 40(02): 168-171. DOI: 10.3971/j.issn.1000-8578.2013.02.011
Citation: Zhu Qingshan, Shen Jing, Wang Nengchao, He Zhijie, Zhang Qingfu, Feng Lianjie. Study of Clinical Staging of Esophageal Cancer Treated by Non-surgical Methods[J]. Cancer Research on Prevention and Treatment, 2013, 40(02): 168-171. DOI: 10.3971/j.issn.1000-8578.2013.02.011

非手术治疗食管癌的临床分期研究

详细信息
    作者简介:

    朱青山(1971-),男,硕士,副主任医师,主要从事肿瘤的放、化疗研究

  • 中图分类号: R735.1

Study of Clinical Staging of Esophageal Cancer Treated by Non-surgical Methods

  • 摘要: 目的验证中国非手术治疗食管癌临床分期专家小组制定的非手术治疗食管癌临床分期标准的临床指导意义,进一步探讨非手术治疗食管癌的预后相关因素,为下一步的分期标准修订提供依据。方法回顾性分析542例经非手术治疗的食管鳞癌患者的临床资料和随访资料,按照中国非手术治疗食管癌临床分期专家小组制定的临床分期标准进行分期,分析不同分期下的生存情况。结果542例患者 1、3、5年生存率分别为86.8%、63.2%、47.3%。不同临床分期的患者比较,总生存时间差异有统计学意义(P<0.0001)。上段食管癌非手术治疗生存期好于中段和下段,差异均有统计学意义(P值分别为0.000和0.004)。不同病理分化程度比较,生存差异同样具有统计学意义(P=0.019)。结论中国食管癌专家组制定的非手术治疗食管癌的临床分期标准,能够较好地估计预后。不同解剖部位和病理分化程度也应作为临床分期的因素予以考虑。

     

    Abstract: ObjectiveTo evaluate the effects of Chinese criteria of clinical staging system for esophageal cancer in the treatment of non-surgical esophageal cancer,and investigate the other factors influenced on prognosis of non-surgical esophageal cancer. Methods All with esophageal squamous cell cancer retrospectively 542 patients were divided into different stages according to the Chinese criteria of clinical staging system for esophageal cancer.OS was analyzed by Kaplan-Meier curves. Results Among the 542 cases,the 1-,3-,5-year survival rates were 86.8%,63.2% and 47.3%,respectively.Significant differences(P=0.000)were shown in different TNM stages.Upper esophageal disease had better prognosis than middle and lower disease(P=0.000 and 0.004).Pathology differentiations were also a factor impacted on the prognosis (P=0.019). Conclusion The Chinese criteria of clinical staging system for esophageal cancer were adaptable to predict prognosis of esophageal squamous cell cancer treated by non-surgical therapy.Anatomic site and Pathology differentiation should also be considered in the staging system.

     

  • [1] Rice TW,Rusch VW,Apperson-Hansen C,et al.Worldwide esophageal cancer collaboration [J].Dis Esophagus,2009,22(1):1-8.
    [2] Chen LQ.Understanding and appraisal of the new TNM classification for esophageal cancer in the AJCC Cancer Staging Manual(7th edition)[J].Zhonghua Zhong Liu Za Zhi,2010,32(3):237-40.[陈龙奇.食管癌国际TNM分期第7版解读与评价[J].中华肿瘤杂志,2010,32(3):237-40.]
    [3] China esophageal non-operative therapy clinical stages of esophageal expert group.Non-operative therapy in patients with cancer of the esophagus standard clinical stages(draft)[J].Zhonghua Fang She Zhong Liu Xue Za Zhi,2010,19(3):179-80.[中国食管癌非手术治疗食管癌临床分期专家小组.非手术治疗食管癌的临床分期标准(草案)[J].中华放射肿瘤学杂志,2010,19(3):179-80.]
    [4] Liu JF,Wang QZ,Hou J.Surgical treatment for cancer of theoesophagus and gastric cancer in Hebei,China[J].Br J Surg,2004,91(1):90-8.
    [5] Koshy M,Esiashvilli N,Landry JC,et al.Multiple Management Modalities in Esophageal Cancer:Epidemiology,Presentation and Progression,Work-up,and Surgical Approaches[J].Oncologist,2004,9(2):137-46.
    [6] Zhang X.Esophageal TNM staging of the present situation and the development trend[J].Zhonghua Zhong Liu Za Zhi,2004,26(11):641-4.[张逊.食管癌TNM分期的现状及发展趋势[J].中华肿瘤杂志,2004,26(11):641-4.]
    [7] Fang WT,Feng J,Mao T,et al.Clinical implications of the new TNM staging system for thoracic esophageal squamous cell carcinoma[J].Zhonghua Zhong Liu Za Zhi,2011,33(9):687-91.[方文涛,冯键,茅腾,等.新版食管癌TNM分期对外科治疗的指导意义[J].中华肿瘤杂志,2011,33(9):687-91.]
    [8] Rice TW,Blackstone EH,Adelstein DJ,et al.Role of clinically determined depth of tumor invasion in the treatment of esophageal carcinoma[J].J Thorac Cardiovasc Surg,2003,125(5):1091-102.
    [9] Han C,Wang L,Zhu SC,et al.Evaluation of prognosis of clinical staging for esophageal carcinoma treated with non-surgical methods-addition with analysis of 225 patients[J].Zhonghua Fang She Zhong Liu Xue Za Zhi,2011,20(2):109-12.[韩春,王澜,祝淑钗,等.非手术治疗食管癌临床分期标准对225例放疗患者的预后评价[J].中华放射肿瘤学杂志,2011,20(2):109-12.]
    [10] Zhao KL,Wang Y,Shi XH.Late course accelerated hyper-fractionated radiotherapy of upper and middle thoracic esophageal T2N0M0 carcinoma[J].Zhonghua Zhong Liu Za Zhi,2002,24(1):80-3.[赵快乐,汪洋,施学辉.临床T2N0M0胸上中段食管癌的后程加速超分割放疗[J].中华肿瘤杂志,2002,24(1):80-3.]
    [11] Cooper JS,Guo MD,Herskovic A,et al.Chemoradiotherapy of locally advanced esophageal cancer:long-term follow-up of a prospective randomized trial(RTOG85-01).Radiation Therapy Oncology Group[J].JAMA,1999,281(17):1623-7.
计量
  • 文章访问数:  2262
  • HTML全文浏览量:  35
  • PDF下载量:  763
  • 被引次数: 0
出版历程
  • 收稿日期:  2012-03-13
  • 修回日期:  2012-07-30
  • 刊出日期:  2013-02-24

目录

    /

    返回文章
    返回
    x 关闭 永久关闭